Evidence map›Paper›PMID 37819650›Full record

SynthesisJAMA psychiatry2024

Normative Modeling of Brain Morphometry in Clinical High Risk for Psychosis.

ENIGMA Clinical High Risk for Psychosis Working Group, Shalaila S Haas, Ruiyang Ge, Ingrid Agartz, G Paul Amminger, Ole A Andreassen, Peter Bachman, Inmaculada Baeza, Sunah Choi, Tiziano Colibazzi and 71 more

Open access · hybridAbstract readMeta-Analysis
In one paragraph

Synthesis in JAMA psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
9.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 51 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Empirical validation of race-neutral normative brain morphometry models across ethnoracially diverse populations.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  7. Review
  8. Article
  9. Normative Modeling of Static and Dynamic Functional Connectivity.bioRxiv : the preprint server for biology · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

81 authors at 20 institutions in 18 countries.

ENIGMA Clinical High Risk for Psychosis Working Group
Shalaila S HaasDepartment of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York.
Ruiyang GeDjavad Mowafaghian Centre for Brain Health, Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada.
Ingrid AgartzDepartment of Psychiatric Research, Diakonhjemmet Hospital, Oslo, Norway.
G Paul AmmingerCentre for Youth Mental Health, University of Melbourne, Melbourne, Victoria, Australia.
Ole A AndreassenKG Jebsen Center for Neurodevelopmental Disorders, University of Oslo, Oslo, Norway.
Peter BachmanDepartment of Psychiatry and Behavioral Sciences, Boston Children's Hospital, Boston, Massachusetts.
Inmaculada BaezaCentro de Investigación Biomédica en Red de Salud Mental (CIBERSAM)-ISCIII, Madrid Spain.
Sunah ChoiDepartment of Brain and Cognitive Sciences, Seoul National University College of Natural Sciences, Seoul, Republic of Korea.
Tiziano ColibazziDepartment of Psychiatry, Columbia University, New York, New York.
Vanessa L CropleyMelbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne and Western Health, Carlton South, VIC, Australia.
Camilo de la Fuente-SandovalLaboratory of Experimental Psychiatry, Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico.
Bjørn H EbdrupCentre for Neuropsychiatric Schizophrenia Research and Centre for Clinical Intervention and Neuropsychiatric Schizophrenia Research, Mental Health Centre Glostrup, University of Copenhagen, Glostrup, Denmark.
Adriana ForteaCentro de Investigación Biomédica en Red de Salud Mental (CIBERSAM)-ISCIII, Madrid Spain.
Paolo Fusar-PoliDepartment of Psychosis Studies, Early Psychosis: Interventions and Clinical-Detection Lab, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
Birte Yding GlenthøjCentre for Neuropsychiatric Schizophrenia Research and Centre for Clinical Intervention and Neuropsychiatric Schizophrenia Research, Mental Health Centre Glostrup, University of Copenhagen, Glostrup, Denmark.
Louise Birkedal GlenthøjCopenhagen Research Center for Mental Health, Mental Health Center Copenhagen, University of Copenhagen, Copenhagen, Denmark.
Kristen M HautDepartment of Psychiatry and Behavioral Sciences, Rush University Medical Center, Chicago, Illinois.
Rebecca A HayesDepartment of Psychiatry and Behavioral Sciences, Boston Children's Hospital, Boston, Massachusetts.
Karsten HeekerenDepartment of Psychiatry and Psychotherapy, LVR-Hospital Cologne, Cologne, Germany.
Christine I HookerDepartment of Psychiatry and Behavioral Sciences, Rush University Medical Center, Chicago, Illinois.
Wu Jeong HwangDepartment of Brain and Cognitive Sciences, Seoul National University College of Natural Sciences, Seoul, Republic of Korea.
Neda JahanshadImaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Marina del Rey.
Michael KaessDepartment of Child and Adolescent Psychiatry, University of Heidelberg, Heidelberg, Germany.
Kiyoto KasaiDepartment of Neuropsychiatry, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Naoyuki KatagiriDepartment of Neuropsychiatry, Toho University School of Medicine, Tokyo, Japan.
Minah KimDepartment of Neuropsychiatry, Seoul National University Hospital, Seoul, Republic of Korea.
Jochen KindlerUniversity Hospital of Child and Adolescent Psychiatry and Psychotherapy, University of Bern, Bern, Switzerland.
Shinsuke KoikeThe University of Tokyo Institute for Diversity and Adaptation of Human Mind, The University of Tokyo, Tokyo, Japan.
Tina D KristensenCentre for Neuropsychiatric Schizophrenia Research, Mental Health Centre Glostrup, Copenhagen University Hospital, Glostrup, Denmark.
Jun Soo KwonDepartment of Neuropsychiatry, Seoul National University Hospital, Seoul, Republic of Korea.
Stephen M LawrieDivision of Psychiatry, University of Edinburgh, Edinburgh, United Kingdom.
Irina LebedevaLaboratory of Neuroimaging and Multimodal Analysis, Mental Health Research Center, Moscow, Russian Federation.
Jimmy LeeDepartment of Psychosis, Institute of Mental Health, Singapore.
Imke L J Lemmers-JansenFaculty of Behavioural and Movement Sciences, Department of Clinical, Neuro and Developmental Psychology, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
Ashleigh LinTelethon Kids Institute, The University of Western Australia, Perth, Western Australia, Australia.
Xiaoqian MaNational Clinical Research Center for Mental Disorders and Department of Psychiatry, The Second Xiangya Hospital of Central South University, Changsha, China.
Daniel H MathalonDepartment of Psychiatry and Behavioral Sciences, University of California, San Francisco, San Francisco.
Philip McGuireDepartment of Psychiatry, University of Oxford, Oxford, United Kingdom.
Chantal MichelUniversity Hospital of Child and Adolescent Psychiatry and Psychotherapy, University of Bern, Bern, Switzerland.
Romina MizrahiDouglas Research Center, McGill Univesity, Montreal, Quebec, Canada.
Masafumi MizunoTokyo Metropolitan Matsuzawa Hospital, Tokyo, Japan.
Paul MøllerDepartment for Mental Health Research and Development, Division of Mental Health and Addiction, Vestre Viken Hospital Trust, Drammen, Norway.
Ricardo Mora-DuránEmergency Department, Hospital Fray Bernardino Álvarez, Mexico City, Mexico.
Barnaby NelsonCentre for Youth Mental Health, University of Melbourne, Melbourne, Victoria, Australia.
Takahiro NemotoDepartment of Neuropsychiatry, Toho University School of Medicine, Tokyo, Japan.
Merete NordentoftCopenhagen Research Center for Mental Health, Mental Health Center Copenhagen, University of Copenhagen, Copenhagen, Denmark.
Dorte NordholmCopenhagen Research Center for Mental Health, Mental Health Center Copenhagen, University of Copenhagen, Copenhagen, Denmark.
Maria A OmelchenkoDepartment of Youth Psychiatry, Mental Health Research Center, Moscow, Russian Federation.
Christos PantelisMelbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne and Western Health, Carlton South, VIC, Australia.
Jose C ParienteMagnetic Resonance Imaging Core Facility, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
Jayachandra M RaghavaCentre for Neuropsychiatric Schizophrenia Research and Centre for Clinical Intervention and Neuropsychiatric Schizophrenia Research, Mental Health Centre Glostrup, University of Copenhagen, Glostrup, Denmark.
Francisco Reyes-MadrigalLaboratory of Experimental Psychiatry, Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico.
Jan I RøssbergOslo University Hospital and University of Oslo, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Wulf RösslerDepartment of Psychiatry and Psychotherapy, Charité Universitätsmedizin, Berlin, Germany.
Dean F SalisburyDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania.
Daiki SasabayashiDepartment of Neuropsychiatry, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan.
Ulrich SchallPriority Centre for Brain and Mental Health Research, The University of Newcastle, Newcastle, New South Wales, Australia.
Lukasz SmigielskiDepartment of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Gisela SugranyesCentro de Investigación Biomédica en Red de Salud Mental (CIBERSAM)-ISCIII, Madrid Spain.
Michio SuzukiDepartment of Neuropsychiatry, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan.
Tsutomu TakahashiDepartment of Neuropsychiatry, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan.
Christian K TamnesDepartment of Psychiatric Research, Diakonhjemmet Hospital, Oslo, Norway.
Anastasia TheodoridouDepartment of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Sophia I ThomopoulosImaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Marina del Rey.
Paul M ThompsonImaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Marina del Rey.
Alexander S TomyshevLaboratory of Neuroimaging and Multimodal Analysis, Mental Health Research Center, Moscow, Russian Federation.
Peter J UhlhaasDepartment of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany.
Tor G VærnesNorwegian Centre for Mental Disorders Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Therese A M J van AmelsvoortDepartment of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Faculty of Health Medicine and Life Sciences, Maastricht University, Maastricht, the Netherlands.
Theo G M van ErpClinical Translational Neuroscience Laboratory, Department of Psychiatry and Human Behavior, University of California, Irvine, Irvine.
James A WaltzMaryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore.
Christina WennebergCopenhagen Research Center for Mental Health, Mental Health Center Copenhagen, University of Copenhagen, Copenhagen, Denmark.
Lars T WestlyeKG Jebsen Center for Neurodevelopmental Disorders, University of Oslo, Oslo, Norway.
Stephen J WoodCentre for Youth Mental Health, University of Melbourne, Melbourne, Victoria, Australia.
Juan H ZhouCenter for Sleep and Cognition, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Dennis HernausDepartment of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Faculty of Health Medicine and Life Sciences, Maastricht University, Maastricht, the Netherlands.
Maria JalbrzikowskiDepartment of Psychiatry and Behavioral Sciences, Boston Children's Hospital, Boston, Massachusetts.
René S KahnDepartment of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York.
Cheryl M CorcoranDepartment of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York.
Sophia FrangouDepartment of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York.
University of Copenhagen · DKUniversity of Oslo · NOIcahn School of Medicine at Mount Sinai · USMental Health Research Center of Russian Academy of Medical Sciences · RUUniversity of Bern · CHUniversity of Southern California · USUniversity of Toyama · JPUniversity of Zurich · CHBoston Children's Hospital · USCharité - Universitätsmedizin Berlin · DEInstituto Nacional de Neurología y Neurocirugía · MXMaastricht University · NLRush University Medical Center · USSeoul National University Hospital · KRThe University of Melbourne · AUThe University of Tokyo · JPToho University · JPCatholic Kwandong University · KRCentral South University · CNCopenhagen University Hospital · DK

Funding

Conduits: Mount Sinai Health System Translational Science HubUL1TR004419 · NCATS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Rosalind J Wright · 2022 to 2026
$46.4M
Research Training in Mood and Anxiety Disorders: From Animal Models to PatientsT32MH015144 · NIMH · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Eduardo David Leonardo · 1985 to 2026
$11.1M
Training U54EB020403 · NIBIB · UNIVERSITY OF SOUTHERN CALIFORNIA · PI THOMPSON, PAUL M · 2014 to 2018
$10.1M
Predicting psychosis risk in youth using a novel structural neuroimaging score that measures deviation from normative development. Can we bring it to communities using portable, low-field MRI?R01MH129636 · NIMH · BOSTON CHILDREN'S HOSPITAL · PI MARIA JALBRZIKOWSKI · 2022 to 2026
$3.8M
Auditory Cortex Connectivity in Emerging PsychosisR01MH113533 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SALISBURY, DEAN F · 2017 to 2021
$3.4M
Optimizing Cognitive Training to Improve Functional Outcome in Clinical High RiskR01MH105246 · NIMH · RUSH UNIVERSITY MEDICAL CENTER · PI HOOKER, CHRISTINE I'LEE · 2014 to 2018
$2.7M
Reward System Function as a Potential Mediator of the Impact of Stress on Psychopathology: A Computational Neuroimaging StudyR01MH115031 · NIMH · UNIVERSITY OF MARYLAND BALTIMORE · PI WALTZ, JAMES A · 2018 to 2022
$2.6M
Training the next generation of clinical neuroscientistsT32MH122394 · NIMH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Rene S. Kahn, ANTONIA S NEW · 2020 to 2026
$2.5M
ENIGMA-SD: Understanding Sex Differences in Global Mental Health through ENIGMAR01MH116147 · NIMH · UNIVERSITY OF SOUTHERN CALIFORNIA · PI THOMPSON, PAUL M · 2018 to 2021
$2.5M
Functional Brain Abnormalities in the Schizophrenia ProdromeR01MH076989 · NIMH · YALE UNIVERSITY · PI MATHALON, DANIEL H · 2007 to 2014
$2.3M
Imaging Alterations in Endocannabinoid Metabolism in Clinical High Risk and First Episode PsychosisR01MH113564 · NIMH · MCGILL UNIVERSITY · PI MIZRAHI, ROMINA · 2017 to 2022
$2.2M
Using the RDoC Approach to Understand Thought Disorder: A Linguistic Corpus-Based ApproachR01MH115332 · NIMH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI CORCORAN, CHERYL MARY · 2018 to 2020
$1.6M
Medical Research Council MR/L011689/1NCATS NIH HHS UL1 TR004419NIBIB NIH HHS U54 EB020403NIMH NIH HHS K01 MH112774NIMH NIH HHS K23 MH085063NIMH NIH HHS R01 MH076989NIMH NIH HHS R01 MH100043NIMH NIH HHS R01 MH105246NIMH NIH HHS R01 MH113533NIMH NIH HHS R01 MH113564NIMH NIH HHS R01 MH115031NIMH NIH HHS R01 MH115332NIMH NIH HHS R01 MH116147NIMH NIH HHS R01 MH123163NIMH NIH HHS R01 MH129636NIMH NIH HHS R21 MH117434NIMH NIH HHS T32 MH015144NIMH NIH HHS T32 MH122394
6 · The paper itself

Abstract

Importance: The lack of robust neuroanatomical markers of psychosis risk has been traditionally attributed to heterogeneity. A complementary hypothesis is that variation in neuroanatomical measures in individuals at psychosis risk may be nested within the range observed in healthy individuals. Objective: To quantify deviations from the normative range of neuroanatomical variation in individuals at clinical high risk for psychosis (CHR-P) and evaluate their overlap with healthy variation and their association with positive symptoms, cognition, and conversion to a psychotic disorder. Design, Setting, and Participants: This case-control study used clinical-, IQ-, and neuroimaging software (FreeSurfer)-derived regional measures of cortical thickness (CT), cortical surface area (SA), and subcortical volume (SV) from 1340 individuals with CHR-P and 1237 healthy individuals pooled from 29 international sites participating in the Enhancing Neuroimaging Genetics Through Meta-analysis (ENIGMA) Clinical High Risk for Psychosis Working Group. Healthy individuals and individuals with CHR-P were matched on age and sex within each recruitment site. Data were analyzed between September 1, 2021, and November 30, 2022. Main Outcomes and Measures: For each regional morphometric measure, deviation scores were computed as z scores indexing the degree of deviation from their normative means from a healthy reference population. Average deviation scores (ADS) were also calculated for regional CT, SA, and SV measures and globally across all measures. Regression analyses quantified the association of deviation scores with clinical severity and cognition, and 2-proportion z tests identified case-control differences in the proportion of individuals with infranormal (z < -1.96) or supranormal (z > 1.96) scores. Results: Among 1340 individuals with CHR-P, 709 (52.91%) were male, and the mean (SD) age was 20.75 (4.74) years. Among 1237 healthy individuals, 684 (55.30%) were male, and the mean (SD) age was 22.32 (4.95) years. Individuals with CHR-P and healthy individuals overlapped in the distributions of the observed values, regional z scores, and all ADS values. For any given region, the proportion of individuals with CHR-P who had infranormal or supranormal values was low (up to 153 individuals [<11.42%]) and similar to that of healthy individuals (<115 individuals [<9.30%]). Individuals with CHR-P who converted to a psychotic disorder had a higher percentage of infranormal values in temporal regions compared with those who did not convert (7.01% vs 1.38%) and healthy individuals (5.10% vs 0.89%). In the CHR-P group, only the ADS SA was associated with positive symptoms (β = -0.08; 95% CI, -0.13 to -0.02; P = .02 for false discovery rate) and IQ (β = 0.09; 95% CI, 0.02-0.15; P = .02 for false discovery rate). Conclusions and Relevance: In this case-control study, findings suggest that macroscale neuromorphometric measures may not provide an adequate explanation of psychosis risk.

Indexed as

Psychotic DisordersAdultBrainCase-Control StudiesCognitionFemaleHumansMaleNeuroimagingProdromal SymptomsYoung Adult

Identifiers

PMID37819650
PMCPMC10568447
OpenAlexW4387540596

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.